In this episode, Tommy and Andrew have another discussion about the rise in popularity of the GLP1 receptor agonist class of drugs for diabetes and weight loss (Ozempic, Wegovy, Saxenda, Mounjaro) including potential benefits, significant harms, and unknown long-term side effects. This is a must-listen for anyone thinking about starting one of these treatments.
Please help us spread the word. Listen, like, share.